Kiniksa Pharmaceuticals International PLC (KNSA) Stock Analysis
Verdict: BUY
ARCALYST market dominance and increased FY26 guidance drive a self-funded growth engine, though high P/E relative to peers invites volatility.
Investment score: 74/100
Analysis as of
Is Kiniksa Pharmaceuticals International PLC stock worth reviewing? AI model thesis
Kiniksa is a rare profitable mid-cap biotech with a dominant product (ARCALYST) and a clear path toward $1.4B+ in annual revenue by 2029.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 90/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 95/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Kiniksa Pharmaceuticals International PLC opportunities and risks
What speaks for KNSA
- ARCALYST Guidance Raise
What speaks against KNSA
- Single-Asset Revenue Concentration
Frequently asked questions about Kiniksa Pharmaceuticals International PLC (KNSA)
Is KNSA stock a good investment?
The cached TradeMates AI model rates Kiniksa Pharmaceuticals International PLC as BUY with an investment score of 74/100. Kiniksa is a rare profitable mid-cap biotech with a dominant product (ARCALYST) and a clear path toward $1.4B+ in annual revenue by 2029. This is algorithmic model output, not personal investment advice.
Is KNSA stock a buy?
The TradeMates model verdict for KNSA is BUY with an investment score of 74/100. Treat this as a model signal to review, not a personal buy recommendation.